Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

计划入组 54 人 · 首次发布于 2019 年 11 月 27 日

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

计划入组 6 人 · 首次发布于 2018 年 9 月 14 日

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

计划入组 600 人 · 首次发布于 2023 年 4 月 24 日

Nadofaragene firadenovec-vncg(Adstiladrin)

Bladder Cancer(Biomics Biotechnologies)

BCG bladder cancer vaccine (Biofabri)

CATALO NATURALS (AUSTRALIA) PTY LTD

Australia

The Cooper Health System, A New Jersey Non-Profit Corporation

United States

CENTER WEST CANCER

United States

Optimizing Outcomes for High-Risk, Non-Muscle-Invasive Bladder Cancer with PD-(L)1 Inhibitors

FDA Approves Nadofaragene Firadenovec as First Gene Therapy for High-Risk Bladder Cancer

CAPS Medical's PlasmaSure System Receives FDA Breakthrough Device Designation for Non-Muscle Invasive Bladder Cancer Treatment